Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term durability of response to adalimumab in Crohn's disease.
Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP. Chaparro M, et al. Among authors: mendoza jl. Inflamm Bowel Dis. 2012 Apr;18(4):685-90. doi: 10.1002/ibd.21758. Epub 2011 May 25. Inflamm Bowel Dis. 2012. PMID: 21618353
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). González-Lama Y, et al. Among authors: mendoza jl. Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6. doi: 10.1157/13125587. Gastroenterol Hepatol. 2008. PMID: 18783686
Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M, Pérez Calle JL, Mendoza JL, Vera MI, Bermejo AF, Sánchez F, López San Román A, Froilán C, González-Lara V, García-Paredes J, Fernández-Blanco I, Abreu L, Casis B, Solís Herruzo JA, Gisbert JP, Maté Jiménez J. Luna-Chadid M, et al. Among authors: mendoza jl. Rev Esp Enferm Dig. 2004 Jun;96(6):379-81; 382-4. doi: 10.4321/s1130-01082004000600003. Rev Esp Enferm Dig. 2004. PMID: 15230667 Free article. English, Spanish.
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Taxonera C, Estellés J, Fernández-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M, Saro C, García-Sánchez V, Gento E, Bastida G, Gisbert JP, Vera I, Martinez-Montiel P, Garcia-Morán S, Sánchez MC, Mendoza JL. Taxonera C, et al. Among authors: mendoza jl. Aliment Pharmacol Ther. 2011 Feb;33(3):340-8. doi: 10.1111/j.1365-2036.2010.04531.x. Epub 2010 Dec 7. Aliment Pharmacol Ther. 2011. PMID: 21133961 Free article.
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, Gisbert JP. Chaparro M, et al. Among authors: mendoza jl. Aliment Pharmacol Ther. 2012 Jan;35(2):275-83. doi: 10.1111/j.1365-2036.2011.04934.x. Epub 2011 Dec 5. Aliment Pharmacol Ther. 2012. PMID: 22142227 Free article.
Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
Medrano LM, Taxonera C, Márquez A, Barreiro-de Acosta M, Gómez-García M, González-Artacho C, Pérez-Calle JL, Bermejo F, Lopez-Sanromán A, Martín Arranz MD, Gisbert JP, Mendoza JL, Martín J, Urcelay E, Núñez C. Medrano LM, et al. Among authors: mendoza jl. Hum Immunol. 2014 Jan;75(1):71-5. doi: 10.1016/j.humimm.2013.09.017. Epub 2013 Oct 10. Hum Immunol. 2014. PMID: 24121042
Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience.
González-Lama Y, Taxonera C, López-Sanromán A, Pérez-Calle JL, Bermejo F, Pajares R, McNicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, Gisbert JP; Madrid Group for Study of Inflammatory Bowel Diseases (ENICMAD). González-Lama Y, et al. Among authors: mendoza j, mendoza jl. Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1086-91. doi: 10.1097/MEG.0b013e3283556db5. Eur J Gastroenterol Hepatol. 2012. PMID: 22713509
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300.
Julià A, Domènech E, Ricart E, Tortosa R, García-Sánchez V, Gisbert JP, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Alonso A, López-Lasanta M, Codó L, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Panés J, Marsal S. Julià A, et al. Among authors: mendoza jl. Gut. 2013 Oct;62(10):1440-5. doi: 10.1136/gutjnl-2012-302865. Epub 2012 Aug 30. Gut. 2013. PMID: 22936669
164 results